Enanta Pharmaceuticals Inc. CEO Jay Luly told BioWorld that, with the FDA's approval for Abbvie Inc.'s hepatitis C virus (HCV) drug Mavyret (glecaprevir/pibrentasvir), his firm is one milestone away from hitting every goal set by the deal.